ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 0.33 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $194,022,823 | +249.6% | 6,877,803 | +113.1% | 3.28% | +222.1% |
| Q1 2023 | $55,504,400 | +27.8% | 3,227,000 | +49.6% | 1.02% | +18.9% |
| Q4 2022 | $43,432,212 | +7.7% | 2,156,515 | +15.9% | 0.86% | +7.9% |
| Q3 2022 | $40,309,000 | +42.9% | 1,861,000 | +85.4% | 0.79% | +31.5% |
| Q2 2022 | $28,212,000 | -19.7% | 1,004,000 | +31.9% | 0.60% | +9.6% |
| Q1 2022 | $35,113,000 | -21.0% | 761,000 | +43.9% | 0.55% | -3.2% |
| Q4 2021 | $44,468,000 | +26.1% | 529,000 | 0.0% | 0.57% | +22.2% |
| Q3 2021 | $35,253,000 | +57.6% | 529,000 | +25.8% | 0.46% | +55.0% |
| Q2 2021 | $22,365,000 | -38.0% | 420,400 | -49.5% | 0.30% | -43.9% |
| Q1 2021 | $36,100,000 | -16.5% | 832,000 | 0.0% | 0.54% | -19.3% |
| Q4 2020 | $43,214,000 | +49.9% | 832,000 | -8.7% | 0.66% | +17.6% |
| Q3 2020 | $28,822,000 | -32.2% | 911,416 | -0.4% | 0.56% | -39.0% |
| Q2 2020 | $42,496,000 | – | 914,705 | – | 0.92% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Mayo Clinic | 442,714 | $14,472,000 | 19.50% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,664,409 | $87,100,000 | 2.14% |
| Matrix Capital Management Company, LP | 3,821,739 | $124,933,000 | 1.66% |
| SECTORAL ASSET MANAGEMENT INC | 556,712 | $18,199,000 | 1.56% |
| Redmile Group, LLC | 2,432,408 | $79,515,000 | 1.46% |
| Avidity Partners Management LP | 904,119 | $29,556,000 | 1.37% |
| SPHERA FUNDS MANAGEMENT LTD. | 194,996 | $6,374,000 | 0.63% |
| Eventide Asset Management | 911,416 | $28,822,000 | 0.56% |
| VIKING GLOBAL INVESTORS LP | 4,443,284 | $145,251,000 | 0.52% |
| Perceptive Advisors | 1,050,003 | $34,325,000 | 0.50% |